Aligos Therapeutics (ALGS)
(Delayed Data from NSDQ)
$19.43 USD
+6.92 (55.32%)
Updated Sep 9, 2024 04:00 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Cash flow Statements
Fiscal Year End for Aligos Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -87.68 | -96.05 | -128.33 | -108.54 | -52.26 |
Depreciation/Amortization & Depletion | 2.65 | 3.52 | 3.86 | 3.56 | 1.42 |
Net Change from Assets/Liabilities | -9.53 | -1.55 | -4.65 | 16.06 | 3.67 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 15.56 | 14.69 | 13.46 | 14.66 | 0.40 |
Net Cash From Operating Activities | -79.00 | -79.39 | -115.66 | -74.26 | -46.77 |
Property & Equipment | -0.02 | -0.94 | -0.89 | -2.06 | -2.79 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 45.00 | -25.35 | 3.91 | 34.82 | 9.58 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 44.98 | -26.29 | 3.02 | 32.76 | 6.79 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 70.98 | 0.23 | 79.63 | 196.93 | 85.58 |
Issuance (Repayment) of Debt | -0.10 | -0.06 | -0.08 | -0.06 | -0.04 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 17.44 | 0.00 | -0.88 | -4.52 | 0.00 |
Net Cash from Financing Activities | 88.33 | 0.16 | 78.68 | 192.35 | 85.53 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 54.31 | -105.52 | -33.96 | 150.84 | 45.56 |
Cash at Beginning of Period | 81.46 | 186.98 | 220.94 | 70.10 | 24.55 |
Cash at End of Period | 135.77 | 81.46 | 186.98 | 220.94 | 70.10 |
Diluted Net EPS | -34.00 | -56.25 | -80.50 | -271.75 | -651.00 |
Fiscal Year End for Aligos Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -29.80 | -34.86 | -87.68 | -59.79 | -41.75 |
Depreciation/Amortization & Depletion | 0.35 | 0.59 | 2.65 | 1.87 | 1.91 |
Net Change from Assets/Liabilities | -1.38 | -5.49 | -9.53 | -9.23 | -3.03 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | -11.40 | 17.02 | 15.56 | 10.81 | 6.86 |
Net Cash From Operating Activities | -42.24 | -22.75 | -79.00 | -56.34 | -36.00 |
Property & Equipment | -0.08 | -0.07 | -0.02 | -0.01 | 0.01 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -48.57 | -88.57 | 45.00 | 45.00 | 44.99 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -48.65 | -88.64 | 44.98 | 44.99 | 45.00 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.30 | 0.00 | 70.98 | 0.48 | 0.48 |
Issuance (Repayment) of Debt | -0.04 | -0.02 | -0.10 | -0.09 | -0.07 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 17.44 | 0.00 | 0.00 |
Net Cash from Financing Activities | 0.26 | -0.02 | 88.33 | 0.39 | 0.41 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -90.63 | -111.41 | 54.31 | -10.96 | 9.41 |
Cash at Beginning of Period | 135.77 | 135.77 | 81.46 | 81.46 | 81.46 |
Cash at End of Period | 45.15 | 24.37 | 135.77 | 70.50 | 90.87 |
Diluted Net EPS | 0.75 | -5.50 | 0.25 | -10.25 | -10.75 |